MY109958A - 5-aryl pyrimidine processes for its production and use as treatment for cns disorders - Google Patents

5-aryl pyrimidine processes for its production and use as treatment for cns disorders

Info

Publication number
MY109958A
MY109958A MYPI91000962A MYPI19910962A MY109958A MY 109958 A MY109958 A MY 109958A MY PI91000962 A MYPI91000962 A MY PI91000962A MY PI19910962 A MYPI19910962 A MY PI19910962A MY 109958 A MY109958 A MY 109958A
Authority
MY
Malaysia
Prior art keywords
processes
treatment
production
cns disorders
pyrimidine
Prior art date
Application number
MYPI91000962A
Other languages
English (en)
Inventor
Alan Skone Philip
Stuart Nobbs Malcolm
John Leach Michael
Iyer Ramachandran
Leonard Yeates Clive
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of MY109958A publication Critical patent/MY109958A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MYPI91000962A 1990-06-01 1991-05-31 5-aryl pyrimidine processes for its production and use as treatment for cns disorders MY109958A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
MY109958A true MY109958A (en) 1997-10-31

Family

ID=10676964

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI91000962A MY109958A (en) 1990-06-01 1991-05-31 5-aryl pyrimidine processes for its production and use as treatment for cns disorders
MYPI95001459A MY136248A (en) 1990-06-01 1991-05-31 Pharmacologically active cns compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI95001459A MY136248A (en) 1990-06-01 1991-05-31 Pharmacologically active cns compounds

Country Status (25)

Country Link
EP (2) EP0679645A1 (online.php)
JP (1) JPH06340634A (online.php)
KR (1) KR920000733A (online.php)
AT (1) ATE141263T1 (online.php)
AU (2) AU652753B2 (online.php)
CA (1) CA2043640A1 (online.php)
CZ (1) CZ281070B6 (online.php)
DE (1) DE69121317T2 (online.php)
DK (1) DK0459819T3 (online.php)
ES (1) ES2093078T3 (online.php)
FI (1) FI912623A7 (online.php)
GB (1) GB9012316D0 (online.php)
GR (1) GR3021237T3 (online.php)
HU (2) HUT58707A (online.php)
IE (1) IE911861A1 (online.php)
IL (2) IL113599A (online.php)
MY (2) MY109958A (online.php)
NO (1) NO180375C (online.php)
NZ (3) NZ238360A (online.php)
PL (2) PL170373B1 (online.php)
PT (1) PT97827B (online.php)
RU (1) RU2091374C1 (online.php)
SK (1) SK278444B6 (online.php)
TW (1) TW224460B (online.php)
ZA (1) ZA914165B (online.php)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての,ピリミジン,ピリジン,プテリジノンおよびインダゾール誘導体
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ES2283315T3 (es) 1999-09-16 2007-11-01 Tanabe Seiyaku Co., Ltd. Compuestos ciclicos de 6 miembros que contienen nitrogeno aromatico.
ATE293962T1 (de) * 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
KR100711042B1 (ko) 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 환상 화합물
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ,インコーポレイテッド 神経栄養活性を有する置換5−アルキニルピリミジン
WO2002068419A1 (en) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用
EP2079732B9 (en) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EA031153B1 (ru) 2011-06-10 2018-11-30 Мерк Патент Гмбх Применение пиримидиновых соединений с btk ингибирующей активностью
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
AU2017283769B2 (en) 2016-06-14 2019-08-15 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EP3568204B1 (en) 2017-01-10 2023-08-30 Novartis AG Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (online.php) *
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
IL98330A (en) 1996-10-31
HUT58707A (en) 1992-03-30
KR920000733A (ko) 1992-01-29
AU652753B2 (en) 1994-09-08
IL113599A0 (en) 1995-08-31
NO180375C (no) 1997-04-09
HU211649A9 (en) 1995-12-28
IL98330A0 (en) 1992-06-21
RU2091374C1 (ru) 1997-09-27
CS164391A3 (en) 1992-02-19
JPH06340634A (ja) 1994-12-13
NZ272001A (en) 1997-03-24
TW224460B (online.php) 1994-06-01
EP0459819A2 (en) 1991-12-04
NO912100D0 (no) 1991-05-31
PL170373B1 (pl) 1996-12-31
FI912623A7 (fi) 1991-12-02
DE69121317T2 (de) 1997-01-02
CZ281070B6 (cs) 1996-06-12
EP0459819B1 (en) 1996-08-14
SK278444B6 (en) 1997-05-07
EP0679645A1 (en) 1995-11-02
DK0459819T3 (da) 1996-09-02
PT97827A (pt) 1992-03-31
IE911861A1 (en) 1991-12-04
EP0459819A3 (en) 1992-03-11
AU7809791A (en) 1991-12-05
AU6745594A (en) 1994-09-15
PT97827B (pt) 1998-10-30
CA2043640A1 (en) 1991-12-02
GR3021237T3 (en) 1997-01-31
MY136248A (en) 2008-08-29
PL166656B1 (pl) 1995-06-30
NO912100L (no) 1991-12-02
ES2093078T3 (es) 1996-12-16
IL113599A (en) 1997-09-30
HU911826D0 (en) 1991-12-30
ZA914165B (en) 1993-03-01
GB9012316D0 (en) 1990-07-18
NZ248501A (en) 1997-03-24
FI912623A0 (fi) 1991-05-31
NZ238360A (en) 1997-03-24
DE69121317D1 (de) 1996-09-19
AU680252B2 (en) 1997-07-24
NO180375B (no) 1996-12-30
ATE141263T1 (de) 1996-08-15

Similar Documents

Publication Publication Date Title
MY115951A (en) Pharmacologically active cns compounds
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
NZ290389A (en) Substituted pyrimidines typically substituted by -piperazin-1-yl
NZ326754A (en) The use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene or salts thereof for the prophylaxis and treatment of sequelae of chronic reduced circulation in the brain in particular strokes and for neurodegenerative disorders
NZ517616A (en) Use of retigabin for treating neuropathic pain
SG43888A1 (en) Novel sulfonylamino pyrimidines
HU9601790D0 (en) Diazabicyclic neurokinin antagonists
UA27748C2 (uk) Похідні піримідину, що мають активність антагоністів ангіотензину іі, спосіб їх отримання та фармацевтична композиція
AU7809791A (en) 5-aryl pyrimidine, processes for its production and use as treatment for CNS disorders
ATE251613T1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
MY121136A (en) Novel heterocyclic sulfonamides.
GB0005345D0 (en) Methods of treating sepsis septic shock and inflammation
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
SI1173439T1 (en) Haloalkoxy imidazonaphthyridines
MY127686A (en) Monofluoroalkyl derivatives
MY121864A (en) Condensed thienopyrimidines with phosphodiesterase-v inhibiting action.
NO951261D0 (no) Opplagring for en del av et banelegeme
IL89278A0 (en) Tetrazole excitatory amino acid receptor antagonists
IL106492A0 (en) Water-dispersible tables
IL162314A0 (en) Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
MXPA02007403A (es) Derivados de pirrol, sustituidos con 4-piridilo y 2,4-pirimidinilo, y su uso en farmacia.
ES2147282T3 (es) Utilizacion de al menos un carburo terpenico y/o uno de sus derivados como adyuvante de un caldo herbicida o coformulante de una composicion herbicida
SG44827A1 (en) Compounds useful as antiproliferative agents and garft inhibitors
EP0464531A3 (en) Enzymatic bating preparations
DK0691846T3 (da) Imidazoquinoxalinoner til behandling af sygdomme i centralnervesystemet